Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2021

View Archived Issues

Equillium presents additional data from EQUALISE study of itolizumab

ON-108600 leads to potent tumor growth inhibition in chemotherapy-resistant TNBC models

Phase Ib/II data reported from CARTITUDE-1 study of ciltacabtagene autoleucel

Preclinical data confirm survival benefit of adding Veyonda to LuPSMA in prostate cancer

lncRNA HULC linked to phenylketonuria prevention, HULC-mimetics show therapeutic promise

B-Raf, MEK1 inhibitors discovered at Chugai

Shenzhen Salubris Pharmaceuticals presents new cathepsin K inhibitors

Shanghai Hengrui Pharmaceutical and others patent ADCs with eribulin derivatives

SSAO inhibitors identified at Shanghai Ennova Biopharmaceutical, Ennovabio Pharmaceuticals

VYNE and In4Derm enter licence agreement for discovery and development of BET inhibitor platform

FDA clears IND application for first-in-human trial of IO-108

Mustang Bio and Mayo Clinic collaborate on development of novel CAR T technology

Sen-Jam and Duke-NUS Medical School partner to develop novel COVID-19 therapy

Cogent initiates phase II study of CGT-9486 in systemic mastocytosis

Nimbus and Schrödinger extend drug discovery collaboration

Moderna initiates phase I/II study of mRNA-3705 in methylmalonic acidemia

Phase I/II study of ChulaCov19 vaccine initiates at Chulalongkorn University

SARS-CoV-2 spike ectodomain protein StriFK vaccine with adjuvant reduces transmission in animals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...